Xin Sun

Xin Sun

Auto-generated profile, based on publicly available information

Xin Sun

Department of Translational Medicine, Jacobio Pharmaceuticals Co., Ltd., Beijing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DKDi Kang
Di Kang
YWYanping Wang
Yanping Wang
YLYiwei Lin
Yiwei Lin
WMWen Wee Ma
Wen Wee Ma
DMDaniel Morgensztern
Daniel Morgensztern
YWYinxiang Wang
Yinxiang Wang
Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.

1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Clinical studies have demonstrated the antitumor efficacy of covalent KRAS G12C inhibitors in treating advanced/metastatic cancers. In the current study, we report the preclinical characteristics of a specific KRAS p.G12C covalent inhibitor, glecirasib. Glecirasib exhibited high potency against KRAS G12C, along with a high level of selectivity over wild-type KRAS, HRAS, and NRAS in biochemical assays. On the cellular level, it substantially reduced downstream ERK and AKT phosphorylation, inhibited the viability of cancer cells harboring the KRAS p.G12C mutation, and demonstrated high selectivity over non-KRAS p.G12C cancer cells. Glecirasib could effectively inhibit HRAS G12C, NRAS G12C, and several G12C-inclusive KRAS double mutants that showed resistance to adagrasib. In vivo research suggested that once-daily dosing of glecirasib can robustly inhibit ERK phosphorylation for at least 24 hours and induced tumor regression in several xenograft models, including the NCI-H1373–luciferase intracranial model. Glecirasib in combination with cetuximab or JAB-3312 (sitneprotafib, a clinical-stage SHP2 inhibitor developed by Jacobio Pharma) significantly enhanced antitumor activity both in vitro and in vivo. Collectively, these results suggest that glecirasib is a potent and selective covalent inhibitor of KRAS G12C, shows potent antitumor activity as monotherapy, and synergizes with either EGFR blockade or SHP2 inhibition. A new drug application for glecirasib has been submitted in China, seeking approval for the treatment of non–small cell lung cancer, supported by a pivotal phase II single-arm study (NCT05009329). Additionally, glecirasib is being explored in clinical trials in combination with cetuximab (phase II, NCT05194995) and JAB-3312 (phase III, NCT06416410). Significance: Glecirasib potently and selectively inhibits KRAS G12C and reduces ERK and AKT phosphorylation in KRAS G12C–mutant cancer cells, further inducing cell-cycle arrest and apoptosis. Glecirasib monotherapy leads to tumor regression in KRAS G12C–mutant animal models and shows synergistic effects with cetuximab or JAB-3312 (sitneprotafib).

15 May 2025
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S6 shows IC50 values in GppNp-bound RAS and cRAF interaction assays.

15 May 2025
Verified
Other
Open access
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Glecirasib inhibited ERK phosphorylation and growth of tumors carrying the KRAS G12C mutation in vivo. A–C, PK/PD studies of a single-dose glecirasib administration in NCI-H358 lung cancer xenograft tumors bearing in the flank of mice. Dose response following a single dose of glecirasib is shown in A. Time-dependent PK/PD properties after a single dose of 30 mg/kg and 100 mg/kg glecirasib are shown in B and C, respectively. After 8 hours, glecirasib concentrations in both plasma and tumor in the 30 mg/kg group, as well as the plasma drug concentration in the 100 mg/kg group, were below the quantification limit (plasma: 1 ng/mL; tumor: 5.5 ng/g). Glecirasib concentrations in plasma and tumor tissue were quantified by LC/MS-MS, whereas p-ERK levels in tumors were measured by HTRF. Three mice per group. D–F,In vivo efficacy studies of glecirasib in CDX models: NCI-H1373 lung cancer (D), NCI-H358 lung cancer (E), and MIA PaCa-2 pancreatic cancer (F). NCI-H1373 and MIA PaCa-2 CDX models: six mice per group; NCI-H358 CDX model: eight mice per group. Glecirasib was administrated once a day orally. G and H, Tumor growth curves (G) and mice body weight curves (H) of the LUN156 lung cancer PDX model after treatment with glecirasib. Six mice per group. All data are represented as the mean ± SEM. conc., concentration; p.o., orally; QD, once a day.

15 May 2025
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S2 shows assay conditions of GppNp-RAS and cRAF interaction assays.

16 March 2026
Verified
Other
Open access
PDF file
PWPeng Wang
Peng Wang
XSXin Sun
Xin Sun
XHXueting He
Xueting He
DKDi Kang
Di Kang
XLXiaoyu Liu
Xiaoyu Liu
YWYanping Wang
Yanping Wang
Table S10 shows the data of in vitro safety panel screening.